Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $346000.0.

  • Nurix Therapeutics' Cash from Investing Activities rose 10024.57% to $346000.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $147.9 million, marking a year-over-year increase of 15737.12%. This contributed to the annual value of $147.9 million for FY2025, which is 15737.12% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Cash from Investing Activities is $346000.0, which was up 10024.57% from $50.5 million recorded in Q3 2025.
  • Nurix Therapeutics' Cash from Investing Activities' 5-year high stood at $71.5 million during Q2 2025, with a 5-year trough of -$140.8 million in Q4 2024.
  • Over the past 5 years, Nurix Therapeutics' median Cash from Investing Activities value was -$1.0 million (recorded in 2021), while the average stood at -$6.1 million.
  • In the last 5 years, Nurix Therapeutics' Cash from Investing Activities tumbled by 234477.74% in 2021 and then surged by 177704.23% in 2022.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Cash from Investing Activities stood at -$36.5 million in 2021, then surged by 250.61% to $55.0 million in 2022, then tumbled by 126.13% to -$14.4 million in 2023, then tumbled by 879.73% to -$140.8 million in 2024, then skyrocketed by 100.25% to $346000.0 in 2025.
  • Its Cash from Investing Activities was $346000.0 in Q4 2025, compared to $50.5 million in Q3 2025 and $71.5 million in Q2 2025.